Who are DTPa-IPV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Infanrix IPV, sIPV+DTaP+MMR, Healive+Healive, Boostrix®-IPV combination vaccine, hepatitis A vaccine, DTaP, PCV10, H-VA dual therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dtpa-ipv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

DTPa-IPV — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DTPa-IPV (DTPa-IPV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination vaccine. Area: Immunology / Infectious Disease Prevention.

phase 3 Combination vaccine Immunology / Infectious Disease Prevention Biologic Live · refreshed every 30 min

Target snapshot

DTPa-IPV (DTPa-IPV) — GlaxoSmithKline. DTPa-IPV is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and poliovirus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DTPa-IPV TARGET	DTPa-IPV	GlaxoSmithKline	phase 3	Combination vaccine
Infanrix IPV	Infanrix IPV	GlaxoSmithKline	marketed	combination vaccine
sIPV+DTaP+MMR	sIPV+DTaP+MMR	China National Biotec Group Company Limited	marketed	Combination vaccine
Healive+Healive	Healive+Healive	Sinovac Biotech Co., Ltd	marketed	Combination vaccine	Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)
Boostrix®-IPV combination vaccine	Boostrix®-IPV combination vaccine	University of Oxford	marketed	combination vaccine
hepatitis A vaccine, DTaP, PCV10	hepatitis A vaccine, DTaP, PCV10	KEMRI-Wellcome Trust Collaborative Research Program	marketed	combination vaccine
H-VA dual therapy	H-VA dual therapy	The First Affiliated Hospital of Nanchang University	marketed	Combination vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination vaccine class)

GlaxoSmithKline · 22 drugs in this class
Sanofi Pasteur, a Sanofi Company · 8 drugs in this class
Serum Institute of India Pvt. Ltd. · 3 drugs in this class
Merck Sharp & Dohme LLC · 3 drugs in this class
Sanofi · 3 drugs in this class
PT Bio Farma · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
The Hospital for Sick Children · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DTPa-IPV — Competitive Intelligence Brief. https://druglandscape.com/ci/dtpa-ipv. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing